{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:23:36Z","timestamp":1748255016755,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Aim<\/jats:title>\n<jats:p>To determine the prevalence of undiagnosed Fabry Disease (FD) in Western Australian (WA) patients undergoing dialysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>FD is a multisystem X-linked lysosomal storage disease caused by deficient activity of alpha-galactosidase-A (\u03b1-GAL-A). Affected individuals are at risk of developing small-fibre neuropathy, rash, progressive kidney disease, hypertrophic cardiomyopathy and ischaemic stroke. Diagnosis is often delayed by years or even decades. Screening high risk population such as dialysis patients may identify patients with undiagnosed Fabry disease.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A cross-sectional study was undertaken of all adult patients receiving dialysis in WA, without previously known FD. After informed consent they were screened for \u03b1-GAL-A activity by dried blood spot samples. Low or inconclusive activity were repeated via Centogene in Rostock, Germany with <jats:italic>GLA<\/jats:italic> genetic analysis. Ethics approval was granted by Royal Perth Hospital Human Research Ethic Committee REG 14\u2013136; site-specific approval was granted from appropriate authorities; ANZ Clinical Trials Registry U1111\u20131163-7629.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Between February 2015 &amp; September 2017, \u03b1-GAL-A activity was performed on 526 patients at 16 dialysis sites. Twenty-nine patients had initial low \u03b1-GAL-A; repeat testing &amp; <jats:italic>GLA<\/jats:italic> genotyping showed no confirmed FD cases. The causes of false positive rates were thought to be secondary to impaired protein synthesis due to patient malnutrition and chronic inflammation, which is common among dialysis patients, in addition to poor sampling handling.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Analysis of this dialysis population has shown a prevalence of 0% undiagnosed FD. False positives results may occur through impaired protein synthesis and sample handling.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-019-1290-3","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T09:02:33Z","timestamp":1578906153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-4552","authenticated-orcid":false,"given":"Sadia","family":"Jahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subashini","family":"Sarathchandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamina","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"2","key":"1290_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91(2):284\u201393.","journal-title":"Kidney Int"},{"issue":"5","key":"1290_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jpeds.2010.02.012","volume":"156","author":"CL Marchesoni","year":"2010","unstructured":"Marchesoni CL, Roa N, Pardal AM, et al. Misdiagnosis in Fabry disease. J Pediatr. 2010;156(5):828\u201331.","journal-title":"J Pediatr"},{"key":"1290_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1290_CR4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","volume":"15","author":"P Kotanko","year":"2004","unstructured":"Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15(5):1323\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1290_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s10157-015-1146-7","volume":"20","author":"O Saito","year":"2016","unstructured":"Saito O, Kusano E, Akimoto T, et al. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol. 2016;20(2):284\u201393.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1290_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2215\/CJN.02490607","volume":"3","author":"J Andrade","year":"2008","unstructured":"Andrade J, Waters PJ, Singh RS, et al. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol. 2008;3(1):139\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1290_CR7","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1021\/ac404000d","volume":"86","author":"M Boutin","year":"2014","unstructured":"Boutin M, Auray-Blais C. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb(3)-related analogues in Fabry disease. Anal Chem. 2014;86(7):3476\u201383.","journal-title":"Anal Chem"},{"issue":"1","key":"1290_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s10038-017-0366-y","volume":"63","author":"YH Lu","year":"2018","unstructured":"Lu YH, Huang PH, Wang LY, et al. Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry. J Hum Genet. 2018;63(1):1\u20138.","journal-title":"J Hum Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1290-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T01:14:16Z","timestamp":1610414056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1290-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1290-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"21 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval was obtained from the Royal Perth Hospital Human Research Ethics Committee REG 14\u2013136. Site-specific approvals were granted from appropriate authorities. This study is registered with ANZ Clinical Trials Registry U1111\u20131163-7629.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}